Omega-3 Fatty Acids for Major Depressive Disorder During Pregnancy

National Science Council, Taiwan

Status: Completed

Conditions: Depressive Disorder

Treatments: Dietary Supplement: Omega-3 fatty acids

Study type: Interventional

Funder types: Other

Identifiers

NCT00618865

NSC 93-2320-B-039-001

Details and patient eligibility

About

Whether high-dose omega-3 fatty acids supplement would be an effective treatment in patients with major depressive disorder during pregnancy and breast-feeding.

Enrollment: 36 patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Eligible participants were pregnant women, aged 18 to 40 years, with major depressive disorder onset between their 16th week (second trimester) and 32nd week (third trimester) of gestation at the Department of Obstetrics.

Exclusion criteria

• Subjects were excluded with a DSM-IV diagnosis of bipolar disorders, psychotic disorders, substance abuse or dependence for at least 3 months, or any Axis-II diagnosis of borderline or antisocial personality disorder.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

36 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

omega-3 fatty acid with 2.2 g of eicosapentanoic acid (EPA) and 1.2 g of docosahexanoic acid (DHA)

Treatment:

Dietary Supplement: Omega-3 fatty acids

2

Placebo Comparator group

Description:

Placebo (olive oil ethyl esters)

Treatment:

Dietary Supplement: Omega-3 fatty acids